NCT04850625已完成不适用
Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: a Multicenter, Retrospective Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 224
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine
详细描述
This is a retrospective study aiming to explore the efficacy and safety of Pyrotinib plus Vinorelbine versus Lapatinib plus Capecitabine in patients with previously treated HER2-positive metastatic breast cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •HER2+ MBC patients scored +3 by immunohistochemical (IHC) analysis or scored +2 and the result of fluorescence in situ hybridization was positive.
- •Patients were previously treated with trastuzumab in the advanced setting and a taxane in any setting.
- •Patients received lapatinib (750-1,250 mg/day) plus capecitabine (1,500-2,000 mg/m2) or pyrotinib (320-400 mg/day) plus vinorelbine (25mg/ m2 intravenously or 60 mg/m2 orally on days 1 and 8 per 21 days) for at least one cycle, starting from Jun 2015 to Jan
- •Patients had complete medical records. All data were retrospectively collected from medical records of individual institutions.
排除标准
- •Incomplete medical history
结局指标
主要结局
PFS
时间窗: 6 weeks
Progression free survival
次要结局
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0(6 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Adjunction with Capecitabin, Lapatinib and Vinorelbin to treat patients with HER2/new-positive, advanced or metastized breast cancer after failure of TrastuzumabFemale patients with HER2/new-positive, locally advanced or metastized breast cancer after failure of chemotherapy with TrastuzumabMedDRA version: 15.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017219-13-DEDeutsche Krebsgesellschaft Sponsor GmbH
Unknown
1 期
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or TrastuzumabHER2 Positive Metastatic Breast CancerNCT02422199Jiangsu HengRui Medicine Co., Ltd.128
已完成
不适用
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus TrastuzumabBreast CancerNCT05572645Fudan University333
进行中（未招募）
3 期
A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast CancerHER2 Positive Metastatic Breast CancerNCT02973737Jiangsu HengRui Medicine Co., Ltd.279
进行中（未招募）
1 期
apatinib versus Lapatinib with Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A randomized phase II trial - Gastro-LapGastric Cancer, cancer of the oesophago-gastric junction, esophageal cancerMedDRA version: 9.1 Level: LLT Classification code 10017758 Term: Gastric cancerMedDRA version: 9.1 Level: LLT Classification code 10015362 Term: Esophageal cancerEUCTR2009-009894-88-DEniversity Hospital of Heidelberg76